Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptor in Non-alcoholic Fatty Liver Disease | ||
| Journal of Nutrition,Fasting and Health | ||
| مقاله 8، دوره 6، شماره 2، شهریور 2018، صفحه 107-114 اصل مقاله (946.11 K) | ||
| نوع مقاله: Research Paper | ||
| شناسه دیجیتال (DOI): 10.22038/jnfh.2018.33580.1124 | ||
| نویسندگان | ||
| Mahmoud Belghaisi-Naseri1؛ Zahra Dehnavi2؛ Farkhonde Razmpour3؛ Mahsa Tousi2؛ Ali Taghipour4؛ Mohsen Nematy5؛ Ali Bahari6؛ Mohsen Azimi-Nezhad* 7 | ||
| 1Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. | ||
| 2Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 3Department of Clinical Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| 4Mashhad university of medical sciences | ||
| 5Department of Nutrition, School of Medicine, Biochemistry and Nutrition, Endoscopic & Minimally Invasive Surgery, and Cancer Research Centers, Mashhad University of Medical Sciences (MUMS), Paradise Daneshgah, Azadi Square, Mashad, Iran | ||
| 6Gastroenterology and Hepatology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. | ||
| 7Department of Medical Genetics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran | ||
| چکیده | ||
| Introduction: Non-alcoholic fatty liver disease (NAFLD) is a clinical pathologic condition, which leads to inflammation events in hepatocytes. The objective of present study was to compare the plasma levels of VEGF and sVEGFR-1 as inflammation factors in overweight and obese children and adolescents with and without NAFLD. Materials and Methods: A total sample of 70 overweight and obese children and adolescents (37 boys and 33 girls) were recruited from those admitted to a nutrition clinic in Mashhad, northeastern Iran. The presence of NAFLD was determined by FibroScan, ultrasound and elevation of liver enzyme. Plasma VEGF and sVEGFR1 were also determined for each individual. Results: VEGF levels (log transformed) showed a significant stepwise increase from “zero” to “first”, “second” and “third” grades (P trend<0.001). However, sVEGFR1 (log transformed) did not show a regular trend between different grades of NAFLD (P trend=0.3). The odds ratios (95% confidence interval) for VEGF across categories of NAFLD were 1.00, 0.99 (0.97-1.01), 1.02 (0.99-1.04), and 1.04 (1.02-1.06). The odds ratios remained relatively unchanged even after adjusting for sex, age and BMI. Conclusion: This study showed a significant positive association between plasma VEGF levels and grades of steatosis in overweight and obese children and adolescents, even after adjustment for age, sex and BMI. | ||
| کلیدواژهها | ||
| Non-alcoholic fatty liver disease؛ VEGF؛ sVEGFR1؛ Children, Adolescents | ||
| مراجع | ||
|
1. Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine. 2002;346(16):1221-31.
2. Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinics in liver disease. 2004;8(4):861-79.
3. Moghaddasifar I, Lankarani K, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. International journal of organ transplantation medicine. 2016;7(3):149.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Non‐Alcoholic Fatty Liver Disease–Meta‐Analytic Assessment of Prevalence, Incidence and Outcomes. Hepatology (Baltimore, Md). 2015.
5. Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PloS one. 2015;10(10):e0140908.
6. Francque S, Laleman W, Verbeke L, Van Steenkiste C, Casteleyn C, Kwanten W, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Laboratory investigation. 2012;92(10):1428-39.
7. Farrell GC, Teoh N, McCuskey R. Hepatic microcirculation in fatty liver disease. The Anatomical Record. 2008;291(6):684-92.
8. Coulon S, Legry V, Heindryckx F, Van Steenkiste C, Casteleyn C, Olievier K, et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology (Baltimore, Md). 2013;57(5):1793-805.
9. Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD. Centrizonal Arteries and Microvessels in Non-Alcoholic Steatohepatitis. The American journal of surgical pathology. 2011;35(9):1400.
10. Sung H-K, Michael IP, Nagy A. Multifaceted role of vascular endothelial growth factor signaling in adult tissue physiology: an emerging concept with clinical implications. Current opinion in hematology. 2010;17(3):206-12.
11. Ferrara N, editor Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Seminars in oncology; 2002: Elsevier.
12. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Molecular endocrinology. 1991;5(12):1806-14.
13. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. The Journal of biological chemistry. 1991;266(18):11947-54.
14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. The FASEB journal. 1999;13(1):9-22.
15. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nature medicine. 2003;9(6):669-76.
16. Jaroszewicz J, Januszkiewicz M, Flisiak R, Rogalska M, Kalinowska A, Wierzbicka I. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment. Cytokine. 2008;44(1):14-7.
17. Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine. 2012;59(2):442-9.
18. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Ozdogan O, Celikel CA, et al. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Archives of medical research. 2011;42(1):38-43.
19. Papageorgiou M-V, Hadziyannis E, Tiniakos D, Georgiou A, Margariti A, Kostas A, et al. Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology. 2017;30(2):209.
20. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clinical science (London, England : 1979). 1998;94(4):395-404.
21. Tayefi M, Shafiee M, Kazemi-Bajestani SMR, Esmaeili H, Darroudi S, Khakpouri S, et al. Depression and anxiety both associate with serum level of hs-CRP: A gender-stratified analysis in a population-based study. Psychoneuroendocrinology. 2017;81:63-9.
22. Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (Baltimore, Md). 2011;53(5):1629-40.
23. Li C-P, Lee F-Y, Hwang S-J, Lu R-H, Lee W-P, Chao Y, et al. Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor. World Journal of Gastroenterology: WJG. 2003;9(12):2832.
24. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of hepatology. 2002;37(1):154-60.
25. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (Baltimore, Md). 1999;29(3):664-9.
26. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. Journal of hepatology. 1997;27(5):854-61.
27. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Research. 1996;56(13):3004-9.
28. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology (Baltimore, Md). 1998;28(1):68-77. | ||
|
آمار تعداد مشاهده مقاله: 1,185 تعداد دریافت فایل اصل مقاله: 1,114 |
||